Roche Launches Subcutaneous Tecentriq in India for Eligible Lung Cancer Patients 

Key Highlights: 

• Roche launched the subcutaneous (SC) formulation of Tecentriq (atezolizumab) in India following approval from the CDSCO for eligible lung cancer patients, expanding access to faster immunotherapy administration in the country 

• The SC version of Tecentriq can be administered in approximately 7 minutes compared to hours required for IV infusion, potentially reducing treatment administration time by ~80%. The formulation combines atezolizumab with Halozyme Therapeutics’ Enhanze drug delivery technology using recombinant human hyaluronidase PH20 (rHuPH20) to enable rapid subcutaneous absorption 

• Tecentriq is indicated as a first-line immunotherapy option for certain lung cancer patients with high PD-L1 expression and is currently approved in 85 countries in both IV and SC formulations. Roche stated that the SC formulation may help reduce hospital burden, lower indirect treatment costs, and improve patient convenience through shorter clinic visits and more decentralized cancer care models 

Implications: 

Tecentriq’s 7‑minute under‑the‑skin version should help Roche deepen its lung cancer business in India by easing pressure on overcrowded infusion centers and making treatment more convenient for patients, which can support broader uptake among eligible PD‑L1–high cases. 

Because it is currently the only PD‑(L)1 in India available as both IV and SC, Tecentriq gains a practical edge in hospital workflows and tenders, and the Enhanze‑based SC platform strengthens Roche’s positioning as payers and providers increasingly value shorter chair time and more decentralized cancer care. 

Source: India Today